Andrea Sartore-Bianchi

Associate Professor

Università degli Studi di Torino

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrea Sartore-Bianchi is an Associate Professor at Università degli Studi di Milano, Italy. Her research focuses on the implications of genetic mutations in cancer treatment, particularly in colorectal cancer and gastric cancers responsive to novel therapies including PARP inhibitors and immune checkpoint inhibitors. She has contributed to various international guidelines and trials aimed at improving patient outcomes in complex cancer cases.

Articles (15)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (16)

VINCENZO MARIA MAZZAFERRO

Full Professor of Surgery

Università degli Studi di Torino

ITALY

Andrea Sartore-Bianchi

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (Frontiers in Oncology, (2022), 12, (1030232), 10.3389/fonc.2022.1030232)

Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review

Delphi initiative for early-onset colorectal cancer (DIRECt). International Management Guidelines

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Collaborators (16)

VINCENZO MARIA MAZZAFERRO

Kevin Monahan

Matteo Benelli

Valentina Giannini

SALVATORE SIENA

Francesco Scaglione

Enrico Berrino

Simone Mazzetti

Angelo Vanzulli

Gianluca Gazzaniga

Antonino Musolino

sara erika bellomo

Sabrina ARENA

Marco Vitellaro

Giovanni Germano

Jeremy Jones

Make your next move.